P1.13A.02 Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage Small Cell Lung Cancer: DeLLphi-305 Phase 3 Trial
M. Pérol, M.-J. Ahn, Yun Cheng, Jennifer Clarke, A.-M. Dingemans, Caryl Gay, A. Navarro, M. Schuler, Takeshi Yoshida, Pablo Martínez, Erik S. Anderson, J. Sands
Topics & Concepts
DurvalumabMedicineStage (stratigraphy)OncologyPhase (matter)Lung cancerCancerInternal medicineImmunotherapyOrganic chemistryChemistryNivolumabBiologyPaleontologyLung Cancer Research StudiesPeptidase Inhibition and AnalysisCancer therapeutics and mechanisms